Clinical Efficacy of Etanercept in Patients with Rheumatoid Arthritis and its Associated Diseases

Clinical Efficacy of Etanercept in Patients with Rheumatoid Arthritis and its Associated Diseases - CLinical Efficacy Of etanercept in PATients with Rheumatoid arthritis and its Associated diseases (CLEOPATRA)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000013368

Enrollment

Registered

2014-03-07

Start date

2011-11-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Rheumatoid arthritis patients with associated diseases refractory to conventional therapies

Exclusion criteria

Exclusion criteria: Rheumatoid arthritis patients with severe pulmonary, renal or cardiac disorders

Design outcomes

Primary

Measure	Time frame
The therapeutic effects and adverse events 52 weeks after the initiation of etanercept	—

Countries

Japan

Contacts

Public ContactTohru Takeuchi

Osaka Medical College Department of Internal Medicine (I)

t-takeuchi@poh.osaka-med.ac.jp072-683-1221

Outcome results